In contrast, Mendes and colleagues [29] estimated that adding NfL to the inclusion criteria for an AD trial in amyloid-PET positive MCI participants could reduce the sample size by up to 25% and in participants with amyloid-PET and tau-PET positivity sample size could be reduced by as much as 50%. Here, MAPT is linked to Alzheimer disease.